167 related articles for article (PubMed ID: 36230709)
1. Treatment of Indolent Cutaneous B-Cell Lymphoma with Intralesional or Intravenous Rituximab.
Menzer C; Rendon A; Hassel JC
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230709
[TBL] [Abstract][Full Text] [Related]
2. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
Kerl K; Prins C; Saurat JH; French LE
Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
[TBL] [Abstract][Full Text] [Related]
3. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma.
Peñate Y; Hernández-Machín B; Pérez-Méndez LI; Santiago F; Rosales B; Servitje O; Estrach T; Fernández-Guarino M; Calzado L; Acebo E; Gallardo F; Salar A; Izu R; Ortiz-Romero PL; Pujol RM; Fernández-de-Misa R
Br J Dermatol; 2012 Jul; 167(1):174-9. PubMed ID: 22356294
[TBL] [Abstract][Full Text] [Related]
4. Primary cutaneous indolent B-cell lymphomas - a retrospective multicenter analysis and a review of literature.
Olszewska-Szopa M; Sobas M; Laribi K; Bao Perez L; Drozd-Sokołowska J; Subocz E; Joks M; Zduniak K; Gajewska M; de Nalecz AK; Romejko-Jarosińska J; Kumiega B; Waszczuk-Gajda A; Wróbel T; Czyz A
Acta Oncol; 2021 Oct; 60(10):1361-1368. PubMed ID: 34346830
[No Abstract] [Full Text] [Related]
5. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab.
Morales AV; Advani R; Horwitz SM; Riaz N; Reddy S; Hoppe RT; Kim YH
J Am Acad Dermatol; 2008 Dec; 59(6):953-7. PubMed ID: 18817999
[TBL] [Abstract][Full Text] [Related]
6. Innovative Therapeutic Approaches in Primary Cutaneous B Cell Lymphoma.
Lang CCV; Ramelyte E; Dummer R
Front Oncol; 2020; 10():1163. PubMed ID: 32850331
[No Abstract] [Full Text] [Related]
7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of intravenous therapy with rituximab in patients with primary cutaneous B-cell lymphomas.
Brandenburg A; Humme D; Terhorst D; Gellrich S; Sterry W; Beyer M
Br J Dermatol; 2013 Nov; 169(5):1126-32. PubMed ID: 23796422
[TBL] [Abstract][Full Text] [Related]
9. A Descriptive Study of 103 Primary Cutaneous B-Cell Lymphomas: Clinical and Pathological Characteristics and Treatment from the Spanish Lymphoma Oncology Group (GOTEL).
Martínez-Banaclocha N; Martínez-Madueño F; Caballé B; Badia J; Blanes M; Bujanda DA; Calvo V; Gómez Codina J; Blanco CQ; Espinosa P; Lavernia J; Arroyo FRG; Risueño MG; Llorca C; Cumeras R; Pulla MP; Gumà J
Cancers (Basel); 2024 Mar; 16(5):. PubMed ID: 38473391
[TBL] [Abstract][Full Text] [Related]
10. Intralesional anti-CD20 antibody for low-grade primary cutaneous B-cell lymphoma: Adverse reactions correlate with favorable clinical outcome.
Eberle FC; Holstein J; Scheu A; Fend F; Yazdi AS
J Dtsch Dermatol Ges; 2017 Mar; 15(3):319-323. PubMed ID: 28177583
[TBL] [Abstract][Full Text] [Related]
11. Long-term Therapeutic Success of Intravenous Rituximab in 26 Patients with Indolent Primary Cutaneous B-cell Lymphoma.
Porkert S; Mai P; Jonak C; Weihsengruber F; Rappersberger K; Bauer W; Simonitsch-Klupp I; Raderer M; Valencak J
Acta Derm Venereol; 2021 Feb; 101(2):adv00383. PubMed ID: 33475146
[TBL] [Abstract][Full Text] [Related]
12. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab.
Kyrtsonis MC; Siakantaris MP; Kalpadakis C; Dimopoulou MN; Vassilakopoulos TP; Kontopidou FN; Antoniou C; Korkolopoulou P; Panayiotidis P; Pangalis GA
Eur J Haematol; 2006 Oct; 77(4):300-3. PubMed ID: 16856917
[TBL] [Abstract][Full Text] [Related]
13. Treatment of primary cutaneous B-cell lymphoma with rituximab.
Fink-Puches R; Wolf IH; Zalaudek I; Kerl H; Cerroni L
J Am Acad Dermatol; 2005 May; 52(5):847-53. PubMed ID: 15858476
[TBL] [Abstract][Full Text] [Related]
14. Primary cutaneous B-cell lymphomas: part II. Therapy and future directions.
Suárez AL; Querfeld C; Horwitz S; Pulitzer M; Moskowitz A; Myskowski PL
J Am Acad Dermatol; 2013 Sep; 69(3):343.e1-11; quiz 355-6. PubMed ID: 23957985
[TBL] [Abstract][Full Text] [Related]
15. Primary Cutaneous B-Cell Lymphoma: Management and Patterns of Recurrence at the Multimodality Cutaneous Lymphoma Clinic of The Ohio State University.
Haverkos B; Tyler K; Gru AA; Winardi FK; Frederickson J; Hastings J; Elkins C; Zhang X; Xu-Welliver M; Wong HK; Porcu P
Oncologist; 2015 Oct; 20(10):1161-6. PubMed ID: 26306900
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous B-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management.
Hristov AC; Tejasvi T; Wilcox RA
Am J Hematol; 2020 Oct; 95(10):1209-1213. PubMed ID: 32815650
[TBL] [Abstract][Full Text] [Related]
17. Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum.
Ferreri AJM; Sassone M; Miserocchi E; Govi S; Cecchetti C; Corti ME; Mappa S; Arcaini L; Zaja F; Todeschini G; Mannina D; Calimeri T; Perrone S; Ponzoni M; Modorati G
Blood Adv; 2020 Mar; 4(6):1013-1019. PubMed ID: 32182364
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous B-cell lymphomas: 2019 update on diagnosis, risk stratification, and management.
Wilcox RA
Am J Hematol; 2018 Nov; 93(11):1427-1430. PubMed ID: 30039522
[TBL] [Abstract][Full Text] [Related]
19. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS
Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in primary cutaneous B-cell lymphomas.
Vermeer MH; Willemze R
Curr Opin Oncol; 2014 Mar; 26(2):230-6. PubMed ID: 24463347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
